XWXianxian Wu

Xianxian Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xianxian Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Dou Shi

    Graduate School of Hebei North University, Zhangjiakou, Hebei Province, 075031, China

    3 shared publications
  • Xing Liu

    Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), National Center of Technology Innovation for Animal Model, NHC Key Laboratory of Human Disease Comparative Medicine, National Human Diseases Animal Model Resource Center, Beijing, 100021, China

    3 shared publications
  • Yang Shi

    China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China

    3 shared publications
  • Zhiwei Yang

    China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, No. 2 Yinghua Yuan East Street, Chaoyang District, Beijing 100029, China

    3 shared publications
  • Hongyu Deng

    Graduate School of Hebei North University, Zhangjiakou, Hebei Province, 075031, China

    2 shared publications
  • Jinyang Zhang

    Graduate School of Hebei North University, Zhangjiakou, Hebei Province, 075031, China

    2 shared publications

Latest Publications

  • G6PD inhibition prevents abdominal aortic aneurysm formation in mice induced by Ang II plus high salt

    by Zhihui Wang, Yang Shi, Dou Shi, Hongyu Deng, Jinyang Zhang, Yuhan Zhang, Xing Liu, Xianxian Wu, Zhiwei Yang

  • Human obese gut microbiota induces lipid metabolic disorder and hypophagia without weight gain in normocaloric mice

    by Yang Shi, Xing Liu, Yun Yang, Hongyu Deng, Jinyang Zhang, Dou Shi, Yuhan Zhang, Yuanzhi Cheng, Yaxi Guo, Hua Zhu, et al.


  • Top Cited Papers
    Open Access

    The Pathophysiological Role of Vascular Smooth Muscle Cells in Abdominal Aortic Aneurysm

    by Dou Shi, Mo Zhang, Yuhan Zhang, Yang Shi, Xing Liu, Xianxian Wu, Zhiwei Yang

    Abdominal aortic aneurysm (AAA) is the most common aortic disease occurring below the renal arteries, caused by multiple etiologies. Currently, no effective drug treatment exists, and the specific pathogenesis remains unclear. Due to its insidious onset and diagnostic challenges, AAA often culminates in aortic rupture, which has a high mortality rate. During AAA development, vascular smooth muscle cells (VSMCs) undergo significant pathological alterations, including contractile dysfunction, phenotypic modulation, cellular degradation, and heightened inflammatory and oxidative stress responses. In particular, emerging evidence implicates vascular smooth muscle cell (VSMC) metabolic dysregulation and mitochondrial dysfunction as key contributors to AAA progression. In this review, we systematically summarize the current understanding of VSMC biology, including their developmental origins, structural characteristics, and functional roles in aortic wall homeostasis, along with the regulatory networks governing the VSMC phenotype and functional maintenance. This review highlights the urgent need for further investigation into the aortic wall VSMC pathophysiology to identify novel therapeutic targets for AAA. These insights may pave the way for innovative treatment strategies in aortic disease management.


  • Open Access

    Kidney Gastrin/CCKBR Attenuates Type 2 Diabetes Mellitus by Inhibiting SGLT2-Mediated Glucose Reabsorption through Erk/NF-κB Signaling Pathway

    by Xue Zhang, Yuhan Zhang, Yang Shi, Dou Shi, Min Niu, Xue Liu, Xing Liu, Zhiwei Yang, Xianxian Wu

    Background: Both sodium-glucose cotransporters (SGLTs) and Na+/H+ exchangers (NHEs) rely on a favorable Na-electrochemical gradient. Gastrin, through the cholecystokinin B receptor (CCKBR), can induce natriuresis and diuresis by inhibiting renal NHEs activity. The present study aims to unveil the role of renal CCKBR in diabetes through SGLT2-mediated glucose reabsorption.Methods: Renal tubule-specific Cckbr-knockout (CckbrCKO) mice and wild-type (WT) mice were utilized to investigate the effect of renal CCKBR on SGLT2 and systemic glucose homeostasis under normal diet, high-fat diet (HFD), and HFD with a subsequent injection of a low dose of streptozotocin. The regulation of SGLT2 expression by gastrin/CCKBR and the underlying mechanism was explored using human kidney (HK)-2 cells.Results: CCKBR was downregulated in kidneys of diabetic mice. Compared with WT mice, CckbrCKO mice exhibited a greater susceptibility to obesity and diabetes when subjected to HFD. In vitro experiments using HK-2 cells revealed an upregulation of glucose transporters after incubation with high glucose, a response that was significantly attenuated following gastrin intervention. The glucose uptake from the culture medium of cells was altered accordingly. Moreover, gastrin administration effectively mitigated hyperglycemia in WT diabetic mice by inhibition of SGLT2 mediated glucose reabsorption, but this effect was compromised in the absence of CCKBR, as seen in CckbrCKO mice. Mechanistically, gastrin/CCKBR substantially reduced SGLT2 expression in HK-2 cells exposed to high glucose, via modulating Erk/nuclear factor-kappa B (NF-κB) pathway.Conclusion: Our study underscores the crucial role of renal gastrin/CCKBR in SGLT2 regulation and glucose reabsorption, and renal gastrin/CCKBR can be a promising therapeutic target for diabetes.